Eculizumab for complement mediated thrombotic microangiopathy in sickle cell disease

Haematologica. 2020 Dec 1;105(12):2887-2891. doi: 10.3324/haematol.2020.262006.

Affiliations

¹ Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, USA.
² Aflac Cancer and Blood Disorders Center, Children Healthcare of Atlanta, Atlanta, GA, USA.
³ Dept. of Pathology, Laboratory Medicine, Emory University School of Medicine, Atlanta, USA.

No abstract available

MeSH terms

Anemia, Sickle Cell* / complications
Anemia, Sickle Cell* / drug therapy
Antibodies, Monoclonal, Humanized / therapeutic use
Complement System Proteins
Humans
Thrombotic Microangiopathies* / drug therapy
Thrombotic Microangiopathies* / etiology

Substances

Antibodies, Monoclonal, Humanized
Complement System Proteins
eculizumab